Aptose Historical Balance Sheet

APTO Stock

USD 0.18 0.01 4.21%

Trend analysis of Aptose Biosciences balance sheet accounts such as Other Current Liab of 9.3 M, Total Current Liabilities of 16 M or Property Plant And Equipment Net of 574.5 K provides information on Aptose Biosciences' total assets, liabilities, and equity, which is the actual value of Aptose Biosciences to its prevalent stockholders. By breaking down trends over time using Aptose Biosciences balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Aptose Biosciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Aptose Biosciences is a good buy for the upcoming year.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptose Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.

About Aptose Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Aptose Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Aptose Biosciences Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Aptose Biosciences and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Aptose currently owns. An asset can also be divided into two categories, current and non-current.

Aptose Biosciences Balance Sheet Chart

At this time, Aptose Biosciences' Other Current Assets are very stable compared to the past year. As of the 11th of December 2024, Other Stockholder Equity is likely to grow to about 75.8 M, while Total Assets are likely to drop about 12.3 M.

Total Assets Total Current Liabilities Property Plant And Equipment Net Net Debt Net Receivables

Add Fundamental

Total Assets

Total assets refers to the total amount of Aptose Biosciences assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Aptose Biosciences books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Aptose Biosciences balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Aptose Biosciences are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Most accounts from Aptose Biosciences' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Aptose Biosciences current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptose Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.At this time, Aptose Biosciences' Other Current Assets are very stable compared to the past year. As of the 11th of December 2024, Other Stockholder Equity is likely to grow to about 75.8 M, while Total Assets are likely to drop about 12.3 M.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	6.0M	5.7M	8.8M	9.3M
Total Assets	82.5M	51.0M	13.0M	12.3M

Other Current Liab Total Assets

Aptose Biosciences balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Non Currrent Assets Other	Intangible Assets	Net Tangible Assets	Common Stock Total Equity	Short Term Debt	Common Stock
Total Assets		0.23	0.25	0.99	0.74	-0.97	-0.39	0.18	0.96	0.55	0.64	1.0	0.51	0.56	0.11	0.43	0.37	0.28	0.08	1.0	-0.02	-0.19	0.93	0.47	0.3	0.72
Other Current Liab	0.23		0.98	0.1	0.56	-0.17	-0.92	0.91	0.2	0.73	-0.08	0.21	0.93	0.16	0.1	0.87	0.95	0.97	0.83	0.23	0.89	-0.27	0.46	0.88	-0.01	0.67
Total Current Liabilities	0.25	0.98		0.12	0.63	-0.21	-0.93	0.97	0.25	0.78	-0.03	0.22	0.94	0.09	0.23	0.87	0.96	1.0	0.81	0.24	0.91	-0.27	0.47	0.88	0.0	0.69
Total Stockholder Equity	0.99	0.1	0.12		0.67	-0.96	-0.27	0.05	0.96	0.46	0.66	0.99	0.4	0.56	0.08	0.32	0.25	0.15	-0.02	0.99	-0.14	-0.16	0.89	0.37	0.31	0.64
Property Plant And Equipment Net	0.74	0.56	0.63	0.67		-0.71	-0.63	0.64	0.72	0.85	0.49	0.73	0.73	0.33	0.32	0.54	0.64	0.65	0.43	0.74	0.46	-0.09	0.75	0.7	0.1	0.81
Net Debt	-0.97	-0.17	-0.21	-0.96	-0.71		0.34	-0.17	-1.0	-0.54	-0.73	-0.97	-0.46	-0.34	-0.16	-0.37	-0.3	-0.24	-0.11	-0.97	0.07	0.2	-0.91	-0.45	-0.39	-0.66
Retained Earnings	-0.39	-0.92	-0.93	-0.27	-0.63	0.34		-0.87	-0.37	-0.72	-0.11	-0.36	-0.95	-0.2	-0.25	-0.85	-0.93	-0.93	-0.67	-0.38	-0.81	0.54	-0.57	-0.94	-0.18	-0.84
Accounts Payable	0.18	0.91	0.97	0.05	0.64	-0.17	-0.87		0.2	0.78	-0.01	0.15	0.88	-0.02	0.33	0.8	0.91	0.97	0.75	0.17	0.93	-0.23	0.38	0.81	-0.07	0.64
Cash	0.96	0.2	0.25	0.96	0.72	-1.0	-0.37	0.2		0.57	0.73	0.96	0.49	0.33	0.17	0.4	0.33	0.28	0.15	0.96	-0.04	-0.21	0.92	0.47	0.4	0.66
Non Current Assets Total	0.55	0.73	0.78	0.46	0.85	-0.54	-0.72	0.78	0.57		0.34	0.53	0.8	0.16	0.24	0.64	0.75	0.8	0.66	0.55	0.63	-0.14	0.66	0.79	0.14	0.65
Other Assets	0.64	-0.08	-0.03	0.66	0.49	-0.73	-0.11	-0.01	0.73	0.34		0.65	0.17	0.03	0.49	-0.07	0.02	-0.01	0.08	0.64	-0.31	-0.15	0.59	0.25	0.4	0.37
Cash And Short Term Investments	1.0	0.21	0.22	0.99	0.73	-0.97	-0.36	0.15	0.96	0.53	0.65		0.49	0.56	0.1	0.4	0.34	0.25	0.06	1.0	-0.05	-0.18	0.92	0.45	0.3	0.7
Common Stock Shares Outstanding	0.51	0.93	0.94	0.4	0.73	-0.46	-0.95	0.88	0.49	0.8	0.17	0.49		0.27	0.16	0.92	0.97	0.94	0.7	0.51	0.79	-0.31	0.67	0.93	0.09	0.84
Short Term Investments	0.56	0.16	0.09	0.56	0.33	-0.34	-0.2	-0.02	0.33	0.16	0.03	0.56	0.27		-0.12	0.25	0.25	0.1	-0.17	0.56	0.01	-0.05	0.49	0.2	-0.16	0.43
Non Current Liabilities Total	0.11	0.1	0.23	0.08	0.32	-0.16	-0.25	0.33	0.17	0.24	0.49	0.1	0.16	-0.12		-0.04	0.16	0.24	0.12	0.1	0.13	-0.3	0.14	0.24	0.18	0.24
Other Current Assets	0.43	0.87	0.87	0.32	0.54	-0.37	-0.85	0.8	0.4	0.64	-0.07	0.4	0.92	0.25	-0.04		0.91	0.86	0.58	0.42	0.78	-0.24	0.58	0.82	0.1	0.73
Other Stockholder Equity	0.37	0.95	0.96	0.25	0.64	-0.3	-0.93	0.91	0.33	0.75	0.02	0.34	0.97	0.25	0.16	0.91		0.96	0.69	0.36	0.85	-0.22	0.54	0.88	0.04	0.77
Total Liab	0.28	0.97	1.0	0.15	0.65	-0.24	-0.93	0.97	0.28	0.8	-0.01	0.25	0.94	0.1	0.24	0.86	0.96		0.81	0.27	0.91	-0.27	0.49	0.88	0.0	0.7
Property Plant And Equipment Gross	0.08	0.83	0.81	-0.02	0.43	-0.11	-0.67	0.75	0.15	0.66	0.08	0.06	0.7	-0.17	0.12	0.58	0.69	0.81		0.08	0.65	-0.11	0.38	0.67	-0.03	0.37
Total Current Assets	1.0	0.23	0.24	0.99	0.74	-0.97	-0.38	0.17	0.96	0.55	0.64	1.0	0.51	0.56	0.1	0.42	0.36	0.27	0.08		-0.02	-0.19	0.93	0.47	0.3	0.71
Non Currrent Assets Other	-0.02	0.89	0.91	-0.14	0.46	0.07	-0.81	0.93	-0.04	0.63	-0.31	-0.05	0.79	0.01	0.13	0.78	0.85	0.91	0.65	-0.02		-0.21	0.16	0.72	-0.2	0.51
Intangible Assets	-0.19	-0.27	-0.27	-0.16	-0.09	0.2	0.54	-0.23	-0.21	-0.14	-0.15	-0.18	-0.31	-0.05	-0.3	-0.24	-0.22	-0.27	-0.11	-0.19	-0.21		-0.29	-0.47	-0.44	-0.45
Net Tangible Assets	0.93	0.46	0.47	0.89	0.75	-0.91	-0.57	0.38	0.92	0.66	0.59	0.92	0.67	0.49	0.14	0.58	0.54	0.49	0.38	0.93	0.16	-0.29		0.66	0.31	0.77
Common Stock Total Equity	0.47	0.88	0.88	0.37	0.7	-0.45	-0.94	0.81	0.47	0.79	0.25	0.45	0.93	0.2	0.24	0.82	0.88	0.88	0.67	0.47	0.72	-0.47	0.66		0.32	0.82
Short Term Debt	0.3	-0.01	0.0	0.31	0.1	-0.39	-0.18	-0.07	0.4	0.14	0.4	0.3	0.09	-0.16	0.18	0.1	0.04	0.0	-0.03	0.3	-0.2	-0.44	0.31	0.32		0.27
Common Stock	0.72	0.67	0.69	0.64	0.81	-0.66	-0.84	0.64	0.66	0.65	0.37	0.7	0.84	0.43	0.24	0.73	0.77	0.7	0.37	0.71	0.51	-0.45	0.77	0.82	0.27

Click cells to compare fundamentals

Aptose Biosciences Account Relationship Matchups

Aptose Biosciences balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	100.5M	126.3M	82.5M	51.0M	13.0M	12.3M
Other Current Liab	3.1M	3.6M	6.0M	5.7M	8.8M	9.3M
Total Current Liabilities	5.5M	6.8M	8.2M	12.3M	15.3M	16.0M
Total Stockholder Equity	93.9M	118.9M	74.2M	37.7M	(2.9M)	(2.8M)
Property Plant And Equipment Net	1.7M	1.2M	788K	1.5M	1.1M	574.5K
Net Debt	(78.3M)	(116.3M)	(38.5M)	(35.7M)	(8.2M)	(8.6M)
Retained Earnings	(301.9M)	(357.2M)	(422.5M)	(464.3M)	(515.5M)	(489.8M)
Accounts Payable	2.0M	2.2M	1.7M	6.3M	6.0M	6.3M
Cash	79.8M	117.4M	39.1M	37.0M	9.3M	15.8M
Non Current Assets Total	1.7M	1.2M	788K	1.5M	1.1M	1.7M
Cash And Short Term Investments	97.6M	122.4M	79.1M	47.0M	9.3M	8.8M
Common Stock Shares Outstanding	3.3M	5.5M	5.9M	6.2M	6.8M	7.1M
Short Term Investments	798K	440K	17.8M	5M	40.0M	10.0M
Liabilities And Stockholders Equity	100.5M	126.3M	82.5M	51.0M	13.0M	12.3M
Non Current Liabilities Total	1.0M	535K	115K	1.0M	621K	590.0K
Other Current Assets	141K	2.7M	2.6M	2.6M	2.6M	2.8M
Other Stockholder Equity	34.6M	50.9M	63.7M	68.9M	72.1M	75.8M
Total Liab	6.6M	7.3M	8.3M	13.3M	15.9M	16.7M
Property Plant And Equipment Gross	1.7M	1.2M	323K	211K	3.9M	4.1M
Total Current Assets	98.8M	125.1M	81.7M	49.5M	11.9M	11.3M
Non Currrent Assets Other	(94.0)	(48.0)	465K	1.3M	1.2M	1.2M
Intangible Assets	1.0	142.0	94.0	48.0	43.2	41.04
Net Tangible Assets	93.8M	118.9M	74.2M	37.7M	43.4M	45.6M
Common Stock Total Equity	365.5M	429.5M	437.4M	437.5M	503.1M	528.3M
Retained Earnings Total Equity	(301.9M)	(357.2M)	(422.5M)	(464.3M)	(417.9M)	(397.0M)
Common Stock	365.5M	429.5M	437.4M	437.5M	444.8M	231.5M
Property Plant Equipment	1.6M	1.1M	788K	211K	189.9K	364.1K
Capital Surpluse	34.6M	50.9M	63.7M	68.9M	79.2M	51.4M
Net Invested Capital	93.9M	118.9M	74.2M	37.7M	(2.9M)	(2.8M)
Net Working Capital	93.2M	118.3M	73.6M	37.2M	(3.4M)	(3.2M)
Capital Stock	365.5M	429.5M	437.4M	437.5M	444.8M	435.6M

Pair Trading with Aptose Biosciences

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aptose Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aptose Biosciences will appreciate offsetting losses from the drop in the long position's value.

Moving together with Aptose Stock

0.8	VALN	Valneva SE ADR	Pair Corr
0.82	ERNA	Eterna Therapeutics	Pair Corr

Moving against Aptose Stock

0.94	DYAI	Dyadic International	Pair Corr
0.83	ESPR	Esperion Therapeutics	Pair Corr
0.68	BMY	Bristol Myers Squibb	Pair Corr
0.46	GILD	Gilead Sciences	Pair Corr
0.41	DNA	Ginkgo Bioworks Holdings	Pair Corr

The ability to find closely correlated positions to Aptose Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aptose Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aptose Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aptose Biosciences to buy it.

The correlation of Aptose Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aptose Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aptose Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Aptose Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Aptose Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aptose Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aptose Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aptose Biosciences Stock:

How To Invest In Aptose

Details

Is Aptose Stock a good investment?

Details

What is Aptose Biosciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.

You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptose Biosciences. If investors know Aptose will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptose Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.92)

Return On Assets

(1.36)

Return On Equity

(6.94)

The market value of Aptose Biosciences is measured differently than its book value, which is the value of Aptose that is recorded on the company's balance sheet. Investors also form their own opinion of Aptose Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Aptose Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptose Biosciences' market value can be influenced by many factors that don't directly affect Aptose Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Aptose Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptose Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptose Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Aptose Historical Balance Sheet

About Aptose Balance Sheet Analysis

Aptose Biosciences Balance Sheet Chart

Total Assets

Total Current Liabilities

Property Plant And Equipment Net

Net Debt

Aptose Biosciences balance sheet Correlations

Aptose Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Aptose Biosciences balance sheet Accounts

Pair Trading with Aptose Biosciences

Moving together with Aptose Stock

Moving against Aptose Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Stockholder Equity	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Stockholder Equity

Cash	- 1.0	Net Debt
Total Current Assets	- 0.97	Net Debt
Cash And Short Term Investments	- 0.97	Net Debt
Net Debt	- 0.97	Total Assets
Net Debt	- 0.96	Total Stockholder Equity
Common Stock Shares Outstanding	- 0.95	Retained Earnings